Details

Autor(en) / Beteiligte

• Seagle, Emma E
• Jackson, Brendan R
• Lockhart, Shawn R
• Georgacopoulos, Ourania
• Nunnally, Natalie S
• Roland, Jeremy
• Barter, Devra M
• Johnston, Helen L
• Czaja, Christopher A
• Kayalioglu, Hazal
• Clogher, Paula
• Revis, Andrew
• Farley, Monica M
• Harrison, Lee H
• Davis, Sarah Shrum
• Phipps, Erin C
• Tesini, Brenda L
• Schaffner, William
• Markus, Tiffanie M
• Lyman, Meghan M

Titel

The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic

Ist Teil von

• Clinical infectious diseases, 2022-03, Vol.74 (5), p.802-811

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2022

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background The COVID-19 pandemic has resulted in unprecedented healthcare challenges, and COVID-19 has been linked to secondary infections. Candidemia, a fungal healthcare-associated infection, has been described in patients hospitalized with severe COVID-19. However, studies of candidemia and COVID-19 coinfection have been limited in sample size and geographic scope. We assessed differences in patients with candidemia with and without a COVID-19 diagnosis. Methods We conducted a case-level analysis using population-based candidemia surveillance data collected through the Centers for Disease Control and Prevention’s Emerging Infections Program during April–August 2020 to compare characteristics of candidemia patients with and without a positive test for COVID-19 in the 30 days before their Candida culture using chi-square or Fisher’s exact tests. Results Of the 251 candidemia patients included, 64 (25.5%) were positive for SARS-CoV-2. Liver disease, solid-organ malignancies, and prior surgeries were each >3 times more common in patients without COVID-19 coinfection, whereas intensive care unit–level care, mechanical ventilation, having a central venous catheter, and receipt of corticosteroids and immunosuppressants were each >1.3 times more common in patients with COVID-19. All-cause in-hospital fatality was 2 times higher among those with COVID-19 (62.5%) than without (32.1%). Conclusions One-quarter of candidemia patients had COVID-19. These patients were less likely to have certain underlying conditions and recent surgery commonly associated with candidemia and more likely to have acute risk factors linked to COVID-19 care, including immunosuppressive medications. Given the high mortality, it is important for clinicians to remain vigilant and take proactive measures to prevent candidemia in patients with COVID-19. We used surveillance data to assess differences in candidemia patients with and without a prior COVID-19 diagnosis. Patients with COVID-19 and candidemia lacked established underlying conditions associated with candidemia but had twice the mortality rate versus candidemia patients without COVID-19.